Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Protein kinase inhibitor Stories

2014-04-09 12:31:42

Initiating Phase Ib studies in NSCLC and AML in 2014 BERGEN, Norway, April 9, 2014 /PRNewswire/ -- BerGenBio AS ("BerGenBio" or the "Company"), an oncology biopharmaceutical company, announces that results from its successful Phase Ia clinical study for lead compound, BGB324, was presented at the American Association of Cancer Research annual conference, which took place on April 5-9, 2014. BGB324 is a first-in-class, highly selective small molecule inhibitor...

2014-03-05 08:29:31

Joint Publication Identifies Clinical Kinase Inhibitors that Potently Cross React with Bromodomain Epigenetic Reader Proteins OXFORD, United Kingdom and FREMONT, Calif., March 5, 2014 /PRNewswire/ -- The Structural Genomics Consortium (SGC) and DiscoveRx Corporation today announced the publication of findings that suggest compelling new multi-targeting approaches for cancer therapy. In a study entitled "Dual kinase-bromodomain inhibitors for rationally designed polypharmacology,"...

2014-02-05 08:28:40

Accelerates development of BGB324, the only selective Axl kinase inhibitor in the clinic BERGEN, Norway, February 5, 2014 /PRNewswire/ -- BerGenBio AS ("BerGenBio" or the "Company"), an oncology biopharmaceutical company, announces that it has raised NOK75 million (c.$12.5 million) from a syndicate of new and existing investors through a private placement. This follows a $6.0 million round in May 2013. Proceeds from the financing will be used to support the development...

2014-01-10 08:23:12

Earns $5.75M Milestone from AstraZeneca for Asthma Partnership SOUTH SAN FRANCISCO, Calif., Jan. 10, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, will present updated product development plans and a financial update at the upcoming 32(nd) Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16th at 9:00 a.m. PT (see webcast details below)....

2014-01-08 08:29:06

SHANGHAI, Jan. 8, 2014 /PRNewswire/ -- Eddingpharm today announced that an asset purchase agreement (APA) has been signed with ACT Biotech, Inc. (ACT Biotech), a biopharmaceutical company based in the United States. Eddingpharm acquired worldwide rights to three small molecule drug assets (Telatinib, ACTB1003, and ACTB1010) and other molecules from ACT Biotech. Eddingpharm made an upfront payment to ACT Biotech upon the closing of the transactions contemplated under the APA. ACT...

2014-01-07 13:48:44

Inhibitors of both JAK and Src kinases represent promising targets for cancer therapeutics because of the central importance of these kinases in tumor cell proliferation and survival. Furthermore, in cancer cells activation of JAK has been reported as a compensatory effect in response to Src inhibitor exposure. This implies simultaneous inhibition of both kinases could have a synergy of anti-cancer effects compared to an agent that inhibits one or the other kinases. The research article by...

2013-11-27 12:22:57

DUBLIN, November 27, 2013 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/p9cqfm/flatrate) has announced the addition of the "Flat-Rate Subscription to La Merie Reports with 24/7 Online Access" [http://www.researchandmarkets.com/research/p9cqfm/flatrate ] subscription to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Subscription to this product provides online access during one year to all reports...

2013-11-07 12:28:12

New targeted treatment delays lung cancer tumour progression and improves disease related symptoms versus standard chemotherapy(i) BURLINGTON, ON, Nov. 7, 2013 /CNW/ - Boehringer Ingelheim (Canada) Ltd. announced today that Health Canada has approved GIOTRIF(®) (afatinib) tablets for oral use, as a new treatment for Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor naïve patients with metastatic (including cytologically proven pleural effusion) adenocarcinoma of...

2013-10-28 08:30:29

Approval of Premium-Priced Novel Agents, Coupled With Rituximab's Continued Dominance, Will Drive a Robust Annual Growth, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 28, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, from 2012 to 2022, the launch of five premium-priced new agents--Johnson & Johnson/Janssen/Pharmacyclics' ibrutinib, Gilead Sciences'...

2013-10-21 10:09:54

The investigational drug AZD9291, a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23. Mutations in the growth factor gene EGFR are present in about 10 to 15 percent of patients with the most common form of lung...